ArticleOncoTargets and therapy2019
Resveratrol Inhibits Proliferation in HBL-52 Meningioma Cells.
Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 11 citations in OpenAlex.
- Hemagglutinating virus of Japan envelope encapsulating microRNA-34a-5p robustly induces apoptosis of malignant meningioma cells by suppressing survivin.Journal of neuro-oncology · 2025Article
- The Potential Application of Resveratrol and Its Derivatives in Central Nervous System Tumors.International journal of molecular sciences · 2024Review
- Noncoding RNA landscape and their emerging roles as biomarkers and therapeutic targets in meningioma.Molecular therapy. Oncology · 2024Review
- Review
- DNA methylation meningioma biomarkers: attributes and limitations.Frontiers in molecular neuroscience · 2023Review
- Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effects of resveratrol on apoptosis and proliferation in meningioma cells and characterize the underlying molecular mechanism.
methodsHBL-52 meningioma cells were treated with resveratrol at doses of 10, 50, 100, 200, and 400 μM for 24, 36, and 48 hrs. Inhibition of proliferation was measured by CCK8 assay, and apoptosis was determined by annexin V staining and flow cytometry. Expression of apoptosis-associated proteins (cleaved-caspase-3, pro-caspase-3) and Bcl-2 were measured by Western blot. Levels of miR-34a-3p and Bcl-2 mRNA were analyzed by reverse transcriptase PCR. A dual luciferase assay was used to determine whether miR-34a-3p binds to the 3'UTR of Bcl-2.
resultsResveratrol reduces proliferation and increases apoptosis in HBL-52 cells. These effects increase with increasing resveratrol concentration and exposure time. Resveratrol increases levels of cleaved-caspase 3 protein as well as decreases levels of pro-caspase 3 protein and Bcl-2 mRNA. The 3'UTR of Bcl-2 contains putative binding sites for miR-34a-3p, and these binding sites can regulate the expression of a luciferase reporter. Overexpression of miR-34a-3p reduces Bcl-2 protein levels in HBL-52 cells.
conclusionResveratrol suppresses proliferation and induces apoptosis in meningioma cells by upregulating miR-34a-3p, which in turn downregulates Bcl-2. Resveratrol may be a useful drug for treating meningiomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.